Sentences with phrase «myeloma therapy»
His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome.
https://warrenalpert.org/
«We believe that the new criteria will rectify the situation where we were unable to use the considerable advances in multiple myeloma therapy prior to organ damage.
As a new member of the elite Multiple Myeloma Research Foundation, we have access to even more new treatments earlier than other facilities, and we are supporting the continued advancement of myeloma therapies.
Not exact matches
«This approval will open the floodgates for these kinds of therapy to be used in many different leukemias, lymphomas, solid tumors, myelomas,» Dr. Prakash Satwani, a pediatric hematologist - oncologist at Columbia University Medical Center, told Business Insider.
So far, its trials have shown it can improve outcomes when used alongside other multiple myeloma drugs and that could offer it some insulation if the market gets disrupted by new treatment approaches, such as gene therapy.
Second, Darzalex secured an important FDA label expansion last year for its use as a second - line multiple myeloma treatment rather than only as a third - line therapy.
«Despite new therapies, it's virtually inevitable that a patient with multiple myeloma will experience relapse of the disease at some point,» said senior author Catriona Jamieson, MD, PhD, professor of medicine, Koman Family Presidential Endowed Chair in Cancer Research and chief of the Division of Regenerative Medicine at UC San Diego School of Medicine.
Despite recent advances, including several new FDA - approved therapies for myeloma, the disease remains incurable, and nearly all patients eventually die from it.
All of the patients in the three trials had myeloma that had either relapsed or become resistant to other therapies.
A phase 3 trial of lenalidomide / dexamethasone with elotuzumab (Empliciti ™), an antibody therapy that attacks myeloma cells directly and spurs the immune system to launch an attack of its own.
Researchers have designed a nanoparticle - based therapy that is effective in treating mice with multiple myeloma, a cancer of immune cells in the bone marrow.
The U.S. Food and Drug Administration approved the drug on Nov. 20 for patients with myeloma who have received at least one previous therapy.
«The significance of this finding gives us a tentative approach to target this marker and could lead to new therapies for this subtype of myeloma.»
«Lenalidomide maintenance therapy improves overall survival for patients with multiple myeloma.»
«Thanks to a deeper understanding of cancer biology, we have a potential new targeted therapy for multiple myeloma, and can better tailor treatment for kids with Wilms tumor.
A randomized phase III trial finding that a new monoclonal antibody, elotuzumab, added to standard therapy, extended the duration of remission for patients with relapsed multiple myeloma by about five months Findings from two phase III studies showing that children with Wilms tumor who have a specific chromosomal abnormality do better with a more intensive, augmented chemotherapy regimen
That trend is problematic considering that African - Americans — the most at - risk population for multiple myeloma — have different genetics that can affect how this type of cancer progresses and what kind of targeted therapies are most effective, said Zarko Manojlovic, lead author of the study.
«The treatment of multiple myeloma has improved significantly in recent years with the introduction of therapies such as proteasome inhibitors [which interfere with tumor cells» protein - disposal system] and potent immuno - modulatory agents,» said the paper's senior author and lead investigator, Paul Richardson, MD, clinical program leader and director of clinical research at Dana - Farber's Jerome Lipper Multiple Myeloma Center, and the R.J. Corman professor at Harvard Medical myeloma has improved significantly in recent years with the introduction of therapies such as proteasome inhibitors [which interfere with tumor cells» protein - disposal system] and potent immuno - modulatory agents,» said the paper's senior author and lead investigator, Paul Richardson, MD, clinical program leader and director of clinical research at Dana - Farber's Jerome Lipper Multiple Myeloma Center, and the R.J. Corman professor at Harvard Medical Myeloma Center, and the R.J. Corman professor at Harvard Medical School.
In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana - Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine.
The authors speculate the reasons for the prolonged survival in their study is that patients with MGUS are evaluated more often for signs of progression to MM and may be diagnosed and started on therapy for myeloma at an earlier stage.
«Our research highlights a potentially new mechanism of dinaciclib action, and raises the possibility that this agent could be a useful addition to current multiple myeloma and myeloid leukemia therapies.»
«T - cell receptor therapy achieves encouraging clinical responses in multiple myeloma: NY - ESO T cell receptor therapy found to be safe, with no cytokine release syndrome cases.»
«Therapy shrinks tumors in patients with multiple myeloma.»
Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT).
One of the biggest questions about the treatment of multiple myeloma, a form of blood cancer, is why nearly all patients treated with current therapies eventually suffer relapse.
If future studies confirm that role, the genes may become targets for therapies that block myeloma metastasis, she added.
A multiple myeloma patient whose cancer had stopped responding after nine different treatment regimens experienced a complete remission after receiving an investigational personalized cellular therapy known as CTL019 developed by a team at the University of Pennsylvania.
The team designed a different approach to study the therapy in myeloma, adding in an infusion of the patient's own stem cells along with their lymphodepleting chemotherapy (melphalan), followed by CTL019 infusion about two weeks later.
The findings of multiple in vivo preclinical studies published online in Blood Advances, a Journal of the American Society of Hematology (ASH), indicate that this therapy could potentially treat multiple cancers, including non-Hodgkin lymphoma (NHL), multiple myeloma (MM), and acute myeloid leukemia (AML).
«Immune therapy might be effective for multiple myeloma.»
P - BCMA - 101 is Poseida's lead CAR - T therapy currently in Phase 1 clinical development for the treatment of multiple myeloma.
-- Poseida Therapeutics released very early data from a Phase 1 study of its CAR - T cell therapy for multiple myeloma.
Multiple myeloma patients got some good news on November 16 — the immunotherapy daratumumab (Darzalex ®) was given approval by the FDA for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy.
Richard Vague, the event's honorary chair, took the podium to acknowledge the vast achievements of the ACC, as did Lori Alf, a multiple myeloma patient of Edward Stadtmauer, MD, chief of Hematologic Malignancies, whose cancer is in remission after receiving chimeric antigen receptor (CAR) therapy.
The company is developing CAR T - cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases.
Her work highlights the need for personalization in the treatment of multiple myeloma — the key is to tailor the therapy in the most appropriate way.
Martin Carroll, MD and Edward Stadtmauer, MD are leading efforts at this TCE to redefine the diagnostic and therapeutic approaches to blood cancers — including leukemia, lymphoma and myeloma — and provide more effective targeted therapies.
The Hematologic Malignancies Translational Center of Excellence (TCE) is a multidisciplinary center that seeks to redefine the diagnostic and therapeutic approaches to blood cancers, including leukemia, lymphoma and myeloma, and provide more effective targeted therapies.
Heidi Simmons decided to focus on cell therapy for treatment of blood cancers like leukemia, lymphoma and myeloma, where healthy cells are infused into patients to replenish those damaged by cancer.
Several types of targeted therapy may be used to treat multiple myeloma and other plasma cell neoplasms.
While myeloma is not curable, it is treatable, especially at a top cancer center like UT Southwestern that has the newest therapies.
CAR T - cell therapy targeting B - cell maturation protein may be a new effective type of immunotherapy treatment for patients with multiple myeloma.
Targeted therapy — the most recent advancement in multiple myeloma treatment, targeted therapies detect and attack cancer cells without damaging normal cells
12 Scientific Sessions Radiochemistry: Imaging of Cancer Other Tumors Basic Science Summary Session One Myeloma and Other Marrow Disorders Radiopharmacy: Quality Control and Validation Radiotherapy and Monitoring Therapy Basic Science Summary Session Two Pre-Clinical Systems Breast Cancer Prostate I: Initial Staging Quantification and Methodology of Oncology Studies Novel Radiochemistry: Radiometals
December 6, 2011 Drug combination highly effective for newly diagnosed myeloma patients, study finds A three - drug combination treatment for the blood cancer multiple myeloma compares favorably to the best established therapy for newly diagnosed patients, according to a multi-center study led by Andrzej Jakubowiak, MD, PhD, professor of medicine and director of the multiple myeloma program at the University of Chicago Medical Center.
His primary research interest is in novel therapies for myeloma, and he has been at the forefront of the clinical development of bortezomib, lenalidomide, and most recently pomalidomide.
The new results — from trials for patients with advanced lymphoma, multiple myeloma, and pancreatic cancer — expand on Penn's work with chimeric antigen receptor (CAR) therapies, building on findings in patients with chronic lymphocytic leukemia and acute lymphoblastic leukemia dating back to the start of the first clinical trial in 2010.
PHILADELPHIA — A multiple myeloma patient whose cancer had stopped responding after nine different treatment regimens experienced a complete remission after receiving an investigational personalized cellular therapy known as CTL019 developed by a team at the University of Pennsylvania.
Multiple myeloma may require symptomatic therapy for pain and for other signs such as kidney malfunction.
Content development for the Functional Assessment of Cancer Therapy - Multiple Myeloma (FACT - MM): use of qualitative and quantitative methods for scale construction